Mitozolomide (M), (NSC 353451) (Stevens et al., 1984) or 8-carbamoyl-3-(2-chloroethyl)-imidazo-[5, 1-d]-l, 2,3,5-tetrazin-4(3H)-one, is a new anticancer agent which has shown striking activity against rodent tumors (Hickman et al., 1985) . Its mechanism of action appears related to the formation of DNA interstrand-cross-links (DNA-ISC) in a manner similar to that described for chloroethylnitrosoureas (Gibson et al., 1984a, b) .
Like the chloroethylnitrosoureas, M does not produce DNA-ISC in cells which are able to remove the crosslinkable monoadducts bound to 06 of guanine (i.e. cells with MER+ phenotype) (Gibson et al., 1984b) . On the other hand, in contrast to the most commonly used chloroethylnitrosoureas (e.g. BCNU), M shows no carbamylating activity (Stevens et al., 1984; Horgan & Tisdale, 1984) and this may perhaps explain some of the differences in its pharmacological effects.
In this study we compared the antiproliferative effects and the perturbation of the cell cycle produced by M and BCNU on the human melanoma cell line, M14, and on the ovarian carcinoma cell line, SW626, and investigated the effects of M on 16 primary cultures of human ovarian cancer cells freshly isolated from patients.
Materials and methods SW626, a human ovarian cancer cell line (Fogh et al., 1977a, b) , was grown at 37°C in air plus 5% CO2 in RPMI 1640 supplemented with 10% FCS, 2mm L-glutamine (Gibco Europe, Glasgow, UK), 10 mM NaHCO3, buffered with HEPES 20mM (Merck, Darmstadt, W. Germany).
The human melanoma cell line M14 (Golub et al., 1976) , was also grown in RPMI 1640 but without HEPES.
The effects of M were studied in primary cultures derived from 6 primary ovarian adenocarcinomas, 2 omental metastases and 8 ascitic fluids from 13 patients. The patients' main characteristics are shown in Table I . In patient no. 9 two paracenteses were performed at intervals of one month. Tumour biopsy specimens were collected in PBS containing 100 U ml -1 penicillin and 100 pig ml -1 streptomycin (Gibco Europe, Glasgow, UK (Colombo et al., 1986) .
Flow cytometry studies were performed on a 30L cytofluorograph (Ortho Instruments, US). Cells in culture were washed with PBS after drug treatment or recovery and directly stained with 2 ml of propidium iodide (PI) solution containing 50 ug ml-1 PI (Calbiochem Behring Co, USA) in 0.1% sodium citrate, 25,ul 1% nonidet P40 as detergent (Sigma) and 25 kI RNAse O.5 ugml-1 in water (Calbiochem Behring Co, USA) at room temperature for 30-40min. With this method nuclei were dislodged from cells adhering to the plastic surface of the 24-well multiwell and entered into suspension without the cells having to be suspended (Colombo et al., 1986) .
The fluorescence pulse was detected in a spectral range between 580 and 750nm. The coefficient of variation (CV) of the GI peak of the cells was 3-4%.
Each cytofluorimetric assay was performed with 2-3 x 105 cells, and the percentage of the cell cycle phases was calculated by the method of Krishan & Frei (1976) .
To determine the DNA index, human leucoytes from freshly collected blood were used as standard. The standard was run before and after the sample to check for drifting of the laser output. The CV of the leucocytes was between 1.5-2.5%. Ploidy was expressed as DNA index, representing the ratio between the GI peak of ovarian cancer cells and the GO/GI peak of leucocytes (Erba et al., 1985) . The effects of M and BCNU on the cell cycle of M 14 and SW626 were assessed by the flow cytometric technique (Figures 3 and 4) ) and in vitro (Horgan et al., 1983) M causes an accumulation of cells in the S late + G2M phase of the cell cycle. At a high concentration M, unlike BCNU, also produces an accumulation of cells in SM phase. This may be related to quantitative or qualitative differences in the binding of the two drugs to DNA and possibly to differences in DNA damage and repair. That the biochemical features of M and BCNU differ is not suprising considering that BCNU causes protein carbamylation whereas M does not (Hickman et al., 1985) . It is known that the formation of DNA-ISC after chloroethylnitrosoureas treatment involves a first rapid alkylation of O6guanine (i.e. chloroethylation or hydroxyethylation) followed by a second reaction with a cytosine located on the opposite strand of DNA (Erickson et al., 1980) . If a cell synthesized O6guanine alkyl transferase (MER+ phenotype) the monoadducts on O6guanine are removed, thus preventing the formation of DNA-ISC. In contrast, in a cell which is O0guanine repair-deficient (MER-phenotype) the monoadduct is not removed and can form DNA-ISC. Both chloroethylnitrosoureas and M induced DNA-ISC appear related to their cytotoxicity (Gibson et al., 1984b) .
However some differences which may perhaps underlie the different perturbation in the cell cycle phases were suggested by Gibson et al. (1984a,b Even though these differences are of biochemical (Hickman et al., 1985) and were cross resistant (Gibson, 1982) . In the present studies the cytotoxicity of M and BCNU against M14 and SW626 human cell lines was also similar.
The indication arising during phase I clinical trials that M might be active against human ovarian carcinoma (Newlands et al., 1985) prompted us to investigate whether human ovarian epithelial cancer cells from biopsies of primary tumours or metastases or from ascitic fluids were sensitive to this agent. Using flow cytometry analysis, a method with proven sensitivity in detecting antiproliferative properties of this drug, we assessed whether M caused cell cycle perturbation on 16 primary cultures of ovarian carcinoma from 13 patients. M was only effective in one case in which a moderate accumulation of cells in S rials and methods. Statistical analysis was by Dunnett's phase was seen. We did not test drug concentrations higher than 10 ,gml-l since a plasma peak level of 7gml-1 M was reported after the dose of 250mgkg-1, i.e. higher than that recommended as safe for further clinical investigations (Newlands et al., 1985) .
Since none of the patients had previously received drugs related to M (i.e. triazenes or nitrosoureas) it may be excluded that resistance was induced by previous treatment, and it appears more likely that ovarian carcinoma cells are naturally non-susceptible to this drug.
Whether this lack of sensitivity is due to these cells' ability to remove 06alkylguanine adducts from DNA or to other mechanisms is now being investigated in our laboratories. 
